Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition

Pablo F. Soto, Chao Xiang Jia, David G. Rabkin, Joseph P. Hart, Yvonne M. Carter, Michael J. Sardo, Daphne T. Hsu, Peter E. Fisher, David J. Pinsky, Henry M. Spotnitz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Inhibition of inducible nitric oxide synthase (nitric oxide II) activity has been proposed as a method to attenuate capillary leak and edema during rejection of heterotopically transplanted rat hearts. Myocardial edema has previously been implicated in diastolic dysfunction during allograft rejection. Accordingly, we tested the hypothesis that inducible nitric oxide synthase inhibition with aminoguanidine would alleviate left ventricular stiffening and myocardial edema formation in 4-day heterotopic rat heart allografts. Methods: Passive left ventricular filling was studied in American Cancer Institute Lewis rats receiving heterotopic heart transplants receiving either aminoguanidine, a selective nitric oxide synthase inhibitor (n = 6); dexamethasone (1 mg · kg-1 · d-1 administered sucutaneously) for 4 days after transplantation (n = 6); or intravenous saline solution (n = 6). American Cancer Institute-to-American Cancer Institute isografts (n = 6) were used as controls. Results: Serum nitrite/nitrate levels in the aminoguanidine group (18 ± 3 mmol/L) and dexamethasone group (22 ± 4 mmol/L) were reduced versus the intravenous saline group (144 ± 36 mmol/L [SEM]) to levels seen in controls (25 ± 9 mmol/L). Left ventricular volume at 15 mm Hg for the aminoguanidine group was increased versus that for the intravenous saline solution group, similar to that for controls, and reduced versus dexamethasone-treated animals. Myocardial water content for the aminoguanidine-treated animals (78.3% ± 0.4%) was similar to those of intravenous saline-treated animals (78.0% ± 0.3%) but greater than those of controls (77.1% ± 0.2%) and dexamethasone- treated animals (76.7% ± 0.3%). Conclusions: Nitric oxide II inhibition with aminoguanidine minimizes the reduction in left ventricular filling that is seen with allograft rejection through a mechanism that is not associated with attenuation of myocardial edema.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalJournal of Thoracic and Cardiovascular Surgery
Volume120
Issue number1
StatePublished - Jul 2000
Externally publishedYes

Fingerprint

Nitric Oxide Synthase Type II
Allografts
Dexamethasone
Edema
Sodium Chloride
Nitric Oxide
Isografts
Neoplasms
Nitrites
Nitric Oxide Synthase
Nitrates
pimagedine
Transplantation
Transplants
Water
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Soto, P. F., Jia, C. X., Rabkin, D. G., Hart, J. P., Carter, Y. M., Sardo, M. J., ... Spotnitz, H. M. (2000). Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition. Journal of Thoracic and Cardiovascular Surgery, 120(1), 39-46.

Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition. / Soto, Pablo F.; Jia, Chao Xiang; Rabkin, David G.; Hart, Joseph P.; Carter, Yvonne M.; Sardo, Michael J.; Hsu, Daphne T.; Fisher, Peter E.; Pinsky, David J.; Spotnitz, Henry M.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 120, No. 1, 07.2000, p. 39-46.

Research output: Contribution to journalArticle

Soto, PF, Jia, CX, Rabkin, DG, Hart, JP, Carter, YM, Sardo, MJ, Hsu, DT, Fisher, PE, Pinsky, DJ & Spotnitz, HM 2000, 'Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition', Journal of Thoracic and Cardiovascular Surgery, vol. 120, no. 1, pp. 39-46.
Soto, Pablo F. ; Jia, Chao Xiang ; Rabkin, David G. ; Hart, Joseph P. ; Carter, Yvonne M. ; Sardo, Michael J. ; Hsu, Daphne T. ; Fisher, Peter E. ; Pinsky, David J. ; Spotnitz, Henry M. / Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition. In: Journal of Thoracic and Cardiovascular Surgery. 2000 ; Vol. 120, No. 1. pp. 39-46.
@article{1fc515b882c34b9c8d708f0a57284f9e,
title = "Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition",
abstract = "Objective: Inhibition of inducible nitric oxide synthase (nitric oxide II) activity has been proposed as a method to attenuate capillary leak and edema during rejection of heterotopically transplanted rat hearts. Myocardial edema has previously been implicated in diastolic dysfunction during allograft rejection. Accordingly, we tested the hypothesis that inducible nitric oxide synthase inhibition with aminoguanidine would alleviate left ventricular stiffening and myocardial edema formation in 4-day heterotopic rat heart allografts. Methods: Passive left ventricular filling was studied in American Cancer Institute Lewis rats receiving heterotopic heart transplants receiving either aminoguanidine, a selective nitric oxide synthase inhibitor (n = 6); dexamethasone (1 mg · kg-1 · d-1 administered sucutaneously) for 4 days after transplantation (n = 6); or intravenous saline solution (n = 6). American Cancer Institute-to-American Cancer Institute isografts (n = 6) were used as controls. Results: Serum nitrite/nitrate levels in the aminoguanidine group (18 ± 3 mmol/L) and dexamethasone group (22 ± 4 mmol/L) were reduced versus the intravenous saline group (144 ± 36 mmol/L [SEM]) to levels seen in controls (25 ± 9 mmol/L). Left ventricular volume at 15 mm Hg for the aminoguanidine group was increased versus that for the intravenous saline solution group, similar to that for controls, and reduced versus dexamethasone-treated animals. Myocardial water content for the aminoguanidine-treated animals (78.3{\%} ± 0.4{\%}) was similar to those of intravenous saline-treated animals (78.0{\%} ± 0.3{\%}) but greater than those of controls (77.1{\%} ± 0.2{\%}) and dexamethasone- treated animals (76.7{\%} ± 0.3{\%}). Conclusions: Nitric oxide II inhibition with aminoguanidine minimizes the reduction in left ventricular filling that is seen with allograft rejection through a mechanism that is not associated with attenuation of myocardial edema.",
author = "Soto, {Pablo F.} and Jia, {Chao Xiang} and Rabkin, {David G.} and Hart, {Joseph P.} and Carter, {Yvonne M.} and Sardo, {Michael J.} and Hsu, {Daphne T.} and Fisher, {Peter E.} and Pinsky, {David J.} and Spotnitz, {Henry M.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "120",
pages = "39--46",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition

AU - Soto, Pablo F.

AU - Jia, Chao Xiang

AU - Rabkin, David G.

AU - Hart, Joseph P.

AU - Carter, Yvonne M.

AU - Sardo, Michael J.

AU - Hsu, Daphne T.

AU - Fisher, Peter E.

AU - Pinsky, David J.

AU - Spotnitz, Henry M.

PY - 2000/7

Y1 - 2000/7

N2 - Objective: Inhibition of inducible nitric oxide synthase (nitric oxide II) activity has been proposed as a method to attenuate capillary leak and edema during rejection of heterotopically transplanted rat hearts. Myocardial edema has previously been implicated in diastolic dysfunction during allograft rejection. Accordingly, we tested the hypothesis that inducible nitric oxide synthase inhibition with aminoguanidine would alleviate left ventricular stiffening and myocardial edema formation in 4-day heterotopic rat heart allografts. Methods: Passive left ventricular filling was studied in American Cancer Institute Lewis rats receiving heterotopic heart transplants receiving either aminoguanidine, a selective nitric oxide synthase inhibitor (n = 6); dexamethasone (1 mg · kg-1 · d-1 administered sucutaneously) for 4 days after transplantation (n = 6); or intravenous saline solution (n = 6). American Cancer Institute-to-American Cancer Institute isografts (n = 6) were used as controls. Results: Serum nitrite/nitrate levels in the aminoguanidine group (18 ± 3 mmol/L) and dexamethasone group (22 ± 4 mmol/L) were reduced versus the intravenous saline group (144 ± 36 mmol/L [SEM]) to levels seen in controls (25 ± 9 mmol/L). Left ventricular volume at 15 mm Hg for the aminoguanidine group was increased versus that for the intravenous saline solution group, similar to that for controls, and reduced versus dexamethasone-treated animals. Myocardial water content for the aminoguanidine-treated animals (78.3% ± 0.4%) was similar to those of intravenous saline-treated animals (78.0% ± 0.3%) but greater than those of controls (77.1% ± 0.2%) and dexamethasone- treated animals (76.7% ± 0.3%). Conclusions: Nitric oxide II inhibition with aminoguanidine minimizes the reduction in left ventricular filling that is seen with allograft rejection through a mechanism that is not associated with attenuation of myocardial edema.

AB - Objective: Inhibition of inducible nitric oxide synthase (nitric oxide II) activity has been proposed as a method to attenuate capillary leak and edema during rejection of heterotopically transplanted rat hearts. Myocardial edema has previously been implicated in diastolic dysfunction during allograft rejection. Accordingly, we tested the hypothesis that inducible nitric oxide synthase inhibition with aminoguanidine would alleviate left ventricular stiffening and myocardial edema formation in 4-day heterotopic rat heart allografts. Methods: Passive left ventricular filling was studied in American Cancer Institute Lewis rats receiving heterotopic heart transplants receiving either aminoguanidine, a selective nitric oxide synthase inhibitor (n = 6); dexamethasone (1 mg · kg-1 · d-1 administered sucutaneously) for 4 days after transplantation (n = 6); or intravenous saline solution (n = 6). American Cancer Institute-to-American Cancer Institute isografts (n = 6) were used as controls. Results: Serum nitrite/nitrate levels in the aminoguanidine group (18 ± 3 mmol/L) and dexamethasone group (22 ± 4 mmol/L) were reduced versus the intravenous saline group (144 ± 36 mmol/L [SEM]) to levels seen in controls (25 ± 9 mmol/L). Left ventricular volume at 15 mm Hg for the aminoguanidine group was increased versus that for the intravenous saline solution group, similar to that for controls, and reduced versus dexamethasone-treated animals. Myocardial water content for the aminoguanidine-treated animals (78.3% ± 0.4%) was similar to those of intravenous saline-treated animals (78.0% ± 0.3%) but greater than those of controls (77.1% ± 0.2%) and dexamethasone- treated animals (76.7% ± 0.3%). Conclusions: Nitric oxide II inhibition with aminoguanidine minimizes the reduction in left ventricular filling that is seen with allograft rejection through a mechanism that is not associated with attenuation of myocardial edema.

UR - http://www.scopus.com/inward/record.url?scp=0034235027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034235027&partnerID=8YFLogxK

M3 - Article

VL - 120

SP - 39

EP - 46

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -